Haoming Wu1,2, Jikun Feng2, Jundong Wu1, Wenjing Zhong2, Xiazi Zouxu2, Weiling Huang2, Xinjian Huang2, Jiarong Yi3, Xi Wang3. 1. The Breast Center, Guangdong Provincial Key Laboratory of Breast Cancer Diagnosis and Treatment, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China. 2. Department of Breast Oncology, The State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. 3. Department of Breast Oncology, The State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. yijr@sysucc.org.cn.
Abstract
BACKGROUND: Triple-negative breast cancer (TNBC) is resistant to targeted therapy with HER2 monoclonal antibodies and endocrine therapy, because it lacks the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). TNBC is a subtype of breast cancer with the worst prognosis and the highest mortality rate compared to other subtypes. N6-methyladenosine (m6A) modification is significant in cancer and metastasis, because it can alter gene expression and function at numerous levels, such as RNA splicing, stability, translocation, and translation. There are limited investigations into the connection between TNBC and m6A. MATERIALS AND METHODS: Breast cancer-related data were retrieved from the Cancer Genome Atlas (TCGA) database, and 116 triple-negative breast cancer cases were identified from the data. The GSE31519 data set, which included 68 cases of TNBC, was obtained from the Gene Expression Omnibus (GEO) database. Survival analysis was used to determine the prognosis of distinct m6A types based on their m6A group, gene group, and m6A score. To investigate the potential mechanism, GO and KEGG analyses were performed on the differentially expressed genes. RESULTS: The expression of m6A-related genes and their impact on prognosis in TNBC patients were studied. According to the findings, m6A was crucial in determining the prognosis of TNBC patients, and the major m6A-linked genes in this process were YTHDF2, RBM15B, IGFBP3, and WTAP. YTHDF2, RBM15B and IGFBP3 are associated with poor prognosis, while WTAP is associated with good prognosis. By cluster analysis, the gene cluster and the m6A cluster were beneficial in predicting the prognosis of TNBC patients. The m6A score based on m6A and gene clusters was more effective in predicting the prognosis of TNBC patients. Furthermore, the tumor microenvironment may play an important role in the process of m6A, influencing TNBC prognosis. CONCLUSIONS: N6-adenylic acid methylation (m6A) was important in altering the prognosis of TNBC patients, and the key m6A-associated genes in this process were YTHDF2, RBM15B, IGFBP3, and WTAP. Furthermore, the comprehensive typing based on m6A and gene clusters was useful in predicting TNBC patients' prognosis, showing potential as valuable evaluating tools for TNBC.
BACKGROUND: Triple-negative breast cancer (TNBC) is resistant to targeted therapy with HER2 monoclonal antibodies and endocrine therapy, because it lacks the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). TNBC is a subtype of breast cancer with the worst prognosis and the highest mortality rate compared to other subtypes. N6-methyladenosine (m6A) modification is significant in cancer and metastasis, because it can alter gene expression and function at numerous levels, such as RNA splicing, stability, translocation, and translation. There are limited investigations into the connection between TNBC and m6A. MATERIALS AND METHODS: Breast cancer-related data were retrieved from the Cancer Genome Atlas (TCGA) database, and 116 triple-negative breast cancer cases were identified from the data. The GSE31519 data set, which included 68 cases of TNBC, was obtained from the Gene Expression Omnibus (GEO) database. Survival analysis was used to determine the prognosis of distinct m6A types based on their m6A group, gene group, and m6A score. To investigate the potential mechanism, GO and KEGG analyses were performed on the differentially expressed genes. RESULTS: The expression of m6A-related genes and their impact on prognosis in TNBC patients were studied. According to the findings, m6A was crucial in determining the prognosis of TNBC patients, and the major m6A-linked genes in this process were YTHDF2, RBM15B, IGFBP3, and WTAP. YTHDF2, RBM15B and IGFBP3 are associated with poor prognosis, while WTAP is associated with good prognosis. By cluster analysis, the gene cluster and the m6A cluster were beneficial in predicting the prognosis of TNBC patients. The m6A score based on m6A and gene clusters was more effective in predicting the prognosis of TNBC patients. Furthermore, the tumor microenvironment may play an important role in the process of m6A, influencing TNBC prognosis. CONCLUSIONS: N6-adenylic acid methylation (m6A) was important in altering the prognosis of TNBC patients, and the key m6A-associated genes in this process were YTHDF2, RBM15B, IGFBP3, and WTAP. Furthermore, the comprehensive typing based on m6A and gene clusters was useful in predicting TNBC patients' prognosis, showing potential as valuable evaluating tools for TNBC.
Authors: Hasanthi C de Silva; Mike Z Lin; Leo Phillips; Janet L Martin; Robert C Baxter Journal: Cell Mol Life Sci Date: 2019-02-06 Impact factor: 9.261
Authors: Patricia Carrera-Lasfuentes; Angel Lanas; Luis Bujanda; Mark Strunk; Enrique Quintero; Santos Santolaria; Rafael Benito; Federico Sopeña; Elena Piazuelo; Concha Thomson; Angeles Pérez-Aisa; David Nicolás-Pérez; Elizabeth Hijona; Jesús Espinel; Rafael Campo; Marisa Manzano; Fernando Geijo; María Pellise; Manuel Zaballa; Ferrán González-Huix; Jorge Espinós; Llúcia Titó; Luis Barranco; Mauro D'Amato; María Asunción García-González Journal: Oncotarget Date: 2017-05-30
Authors: Jaclyn M Einstein; Mark Perelis; Isaac A Chaim; Jitendra K Meena; Julia K Nussbacher; Alexandra T Tankka; Brian A Yee; Heyuan Li; Assael A Madrigal; Nicholas J Neill; Archana Shankar; Siddhartha Tyagi; Thomas F Westbrook; Gene W Yeo Journal: Mol Cell Date: 2021-07-02 Impact factor: 19.328
Authors: Deobrat Dixit; Briana C Prager; Ryan C Gimple; Hui Xian Poh; Yang Wang; Qiulian Wu; Zhixin Qiu; Reilly L Kidwell; Leo J Y Kim; Qi Xie; Kristoffer Vitting-Seerup; Shruti Bhargava; Zhen Dong; Li Jiang; Zhe Zhu; Petra Hamerlik; Samie R Jaffrey; Jing Crystal Zhao; Xiuxing Wang; Jeremy N Rich Journal: Cancer Discov Date: 2020-10-06 Impact factor: 39.397